Trial reportPloS one2015
Lactobacillus casei Shirota Supplementation Does Not Restore Gut Microbiota Composition and Gut Barrier in Metabolic Syndrome: A Randomized Pilot Study.
Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01182844 (Obesity - Inflammation - Metabolic Disease), which is not on this map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Obesity - Inflammation - Metabolic Disease: Effect of Lactobacillus Casei Shirota
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- The Effects of Prebiotic Dietary Fibers, Probiotics, and Synbiotics on Gut Permeability and Immunity: A Systematic Review.Iranian journal of medical sciences · 2025Pooled it
- A Meta-Analysis of Microbial Therapy Against Metabolic Syndrome: Evidence From Randomized Controlled Trials.Frontiers in nutrition · 2021Pooled it
- Effects of Probiotics on Metabolic Syndrome: A Systematic Review of Randomized Clinical Trials.Nutrients · 2020Pooled it
- Effects of Bifidobacterium animalis ssp. lactis 420 on gastrointestinal inflammation induced by a nonsteroidal anti-inflammatory drug: A randomized, placebo-controlled, double-blind clinical trial.British journal of clinical pharmacology · 2021Trial
- Effect of the Intake of a Traditional Mexican Beverage Fermented with Lactic Acid Bacteria on Academic Stress in Medical Students.Nutrients · 2021Trial
- A Double-Blind, Randomized Placebo-Controlled Trial of ProbioticNutrients · 2020Trial
- Effects of Regular Kefir Consumption on Gut Microbiota in Patients with Metabolic Syndrome: A Parallel-Group, Randomized, Controlled Study.Nutrients · 2019Trial
- Trial
- Probiotic reduces bacterial translocation in type 2 diabetes mellitus: A randomised controlled study.Scientific reports · 2017Trial
- Microbiota-Gut-Brain Axis Disruption, Neuroinflammation, and Potential Antioxidant-Based Treatments in Metabolic Diseases.Antioxidants (Basel, Switzerland) · 2026Review
- Bioactive compounds as therapeutic modulators of metabolic syndrome: targeting inflammation and gut microbiota regulation.Frontiers in physiology · 2026Review
- Therapeutic Strategies to Modulate Gut Microbial Health: Approaches for Chronic Metabolic Disorder Management.Metabolites · 2025Review
- The effects of powdered drinks enriched with curcumin and probiotics on lipid profile and atherogenic indices in patients with metabolic syndrome: A randomized, double-blinded, placebo-controlled clinical trial.Food science & nutrition · 2024Article
- Research advances in the therapy of metabolic syndrome.Frontiers in pharmacology · 2024Review
- The Black Box Orchestra of Gut Bacteria and Bile Acids: Who Is the Conductor?International journal of molecular sciences · 2023Review
- Biotechnological Applications of Probiotics: A Multifarious Weapon to Disease and Metabolic Abnormality.Probiotics and antimicrobial proteins · 2022Review
- Microbiota Modulation in Patients with Metabolic Syndrome.Nutrients · 2022Review
- Metabolic Syndrome: Updates on Pathophysiology and Management in 2021.International journal of molecular sciences · 2022Review
- Traditional Chinese Medicine Formula Jian Pi Tiao Gan Yin Reduces Obesity in Mice by Modulating the Gut Microbiota and Fecal Metabolism.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
Abstract
unlabelledMetabolic syndrome is associated with disturbances in gut microbiota composition. We aimed to investigate the effect of Lactobacillus casei Shirota (LcS) on gut microbiota composition, gut barrier integrity, intestinal inflammation and serum bile acid profile in metabolic syndrome. In a single-centre, prospective, randomised controlled pilot study, 28 subjects with metabolic syndrome received either LcS for 12 weeks (n = 13) or no LcS (n = 15). Data were compared to healthy controls (n = 16). Gut microbiota composition was characterised from stool using 454 pyrosequencing of 16S rRNA genes. Serum bile acids were quantified by tandem mass spectrometry. Zonulin and calprotectin were measured in serum and stool by ELISA. Bacteroidetes/Firmicutes ratio was significantly higher in healthy controls compared to metabolic syndrome but was not influenced by LcS. LcS supplementation led to enrichment of Parabacteroides. Zonulin and calprotectin were increased in metabolic syndrome stool samples but not influenced by LcS supplementation. Serum bile acids were similar to controls and not influenced by LcS supplementation. Metabolic syndrome is associated with a higher Bacteroidetes/Firmicutes ratio and gut barrier dysfunction but LcS was not able to change this. LcS administration was associated with subtle microbiota changes at genus level.
trial registrationClinicalTrials.gov NCT01182844.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.